On July 23, Danaher rose 4.25% in regular trading, trading at 186.34 USD/share, with turnover of $104 million, staging a recovery bounce after two consecutive sessions of cumulative decline of approximately 20%.

The prior sell-off was triggered by the company's Q2 earnings release on July 21, where despite beating expectations with adjusted EPS of $1.94 (vs. $1.83 estimate) and revenue of $6.265 billion (vs. $6.102 billion estimate), management guided Q3 non-GAAP core revenue growth of only 2.0%-3.0%, significantly below Q2 momentum. Post-earnings, Morgan Stanley cut its target to $220 from $255 and Evercore ISI reduced to $205 from $230, though both maintained buy ratings. The current mean analyst target of $227.50 remains well above the trading price, providing valuation support for the rebound.

Within the Life Sciences Tools and Services sector, broad strength reinforced momentum, with Thermo Fisher Scientific up 9.14%, Medpace up 22.13%, and Waters up 3.18%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)